Navigation Links
Cornerstone Therapeutics Receives Approval to Acquire Commercial Rights to the Antibiotic Factive(R)
Date:9/3/2009

CARY, N.C., Sept. 3 /PRNewswire-FirstCall/ -- Cornerstone Therapeutics Inc. (Nasdaq: CRTX), a specialty pharmaceutical company focused on acquiring, developing and commercializing significant products primarily for the respiratory and related markets, today announced that it has received the approval of the United States Bankruptcy Court for the District of Massachusetts for its acquisition of the commercial rights to the antibiotic Factive(R) (gemifloxacin mesylate) in North America and certain countries in Europe from Oscient Pharmaceuticals Corporation (OSCIQ.PK) and expects to promptly close the transaction. At the closing, the Company will purchase the Factive assets for a cash payment of $5,000,000 plus an amount for purchased inventory to be mutually determined prior to closing, quarterly royalty payments based on adjusted net sales for a period of five years and the assumption of certain liabilities, including aggregate cure amounts of $110,000 under certain contracts that were assumed by the Company. Oscient filed its voluntary petition for relief under Chapter 11 of the United States Bankruptcy Code with the United States Bankruptcy Court for the District of Massachusetts on July 13, 2009.

Factive is a fluoroquinolone antibiotic approved for the treatment of acute bacterial exacerbations of chronic bronchitis (ABECB) and community-acquired pneumonia of mild to moderate severity (CAP). According to Wolters Kluwer Health, a third-party provider of prescription data, in 2008, the U.S. oral solid fluoroquinolone market generated approximately 39 million prescriptions. Factive was launched in the U.S. in September of 2004 and is the only fluoroquinolone approved in the U.S. for the five-day treatment of both ABECB and CAP. Approximately 1.1 million prescriptions have been dispensed for F
'/>"/>

SOURCE Cornerstone Therapeutics Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Cornerstone Therapeutics Announces Closing of Chiesi Transaction
2. Cornerstone Therapeutics Inc. Announces Record Date and Meeting Date for Special Meeting of Stockholders for Vote with Respect to Charter Amendments
3. Cornerstone Therapeutics to Present at BioCenturys 2009 Future Leaders in the Biotech Industry Conference
4. Cornerstone Therapeutics Reports Year Ended December 31, 2008 Financial Results
5. Cornerstone Therapeutics to Host Quarter and Year Ended December 31, 2008 Conference Call
6. Cornerstone Therapeutics Provides Update on Integration Activities and Issues 2008 Revenue Guidance
7. Cell Therapeutics, Inc. (CTI) to Present at Rodman & Renshaw Healthcare Conference
8. PTC Therapeutics Announces Celgene Exercised Option to Drug Discovery Collaboration
9. PTC Therapeutics Announces Drug Discovery Collaboration With Roche
10. United Therapeutics Corporation Announces Stock Split To Be Effected as a Stock Dividend
11. Oxygen Biotherapeutics, Inc. to Present at Investment Conferences in New York and Zurich
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... the course of a day - car, phone, ... the chemical industry to turn raw materials such ... valuable chemicals that are the ingredients of life,s ... who achieved outstanding progress in driving this energy ... light instead of fossil fuels, has won the ...
(Date:9/18/2014)... CA (PRWEB) September 18, 2014 ... which include Sartorius/Biohit, Socorex, Capp, and AccuPet brand ... volumes of 100 uL or less and are ... and forensic applications. , The micropipette promotions ... quality and economic alternative products to help customers ...
(Date:9/17/2014)... 17, 2014  PDL BioPharma, Inc. (PDL) (NASDAQ: ... firm, Ernst & Young LLP ("EY") that it was resigning ... letter delivered to the Company on September 15, 2014 and ... PDL has issued the following statement in ... number of inquiries on the reason for the resignation of ...
(Date:9/17/2014)... , Sept. 17, 2014 /PRNewswire/ - Oncothyreon Inc. ... intends to offer and sell shares of its Common ... but concurrent underwritten public offerings.  The Series A Convertible ... Oncothyreon Common Stock, provided that conversion will be prohibited ... would beneficially own more than 4.99% of the Common ...
Breaking Biology Technology:Using solar energy to turn raw materials into ingredients for every day life 2Major Pipette Distributor Pipette.com Announces Promotions on Sartorius/Biohit, Socorex, Capp, and AccuPet Micropipettes 2Major Pipette Distributor Pipette.com Announces Promotions on Sartorius/Biohit, Socorex, Capp, and AccuPet Micropipettes 3PDL BioPharma Issues Statement on Resignation of Ernst and Young as Corporate Auditors 2PDL BioPharma Issues Statement on Resignation of Ernst and Young as Corporate Auditors 3Oncothyreon Announces Proposed Public Offerings 2
... , High-level expression of difficult heterologous proteins ... has created variants of the Epicurian Coli ... of strains, which contain extra copies of the E. ... for a high-level,expression of proteins that are difficult to ...
... primary libraries with new plasmid library construction,kits , ... Barry,Neiditch Alan Greener John C. Bauer ... II,pcmv-script and pAD-GAL4-2.1 XR library ... into Epicurian Coli ,XL10-Gold ...
... , , , ,Over 40% of Stratagenes GeneConnection cDNA ... estimated to be full-length clones , Jason Goncalves ... GeneConnection discovery cDNA clone collection YY ... many ,different human tissues and has identified thousands of ...
Cached Biology Technology:Codon Bias-Adjusted BL21 Derivatives for Protein Expression 2Codon Bias-Adjusted BL21 Derivatives for Protein Expression 3Codon Bias-Adjusted BL21 Derivatives for Protein Expression 4Codon Bias-Adjusted BL21 Derivatives for Protein Expression 5Codon Bias-Adjusted BL21 Derivatives for Protein Expression 6Codon Bias-Adjusted BL21 Derivatives for Protein Expression 7Generate High-Quality, Directional Plasmid cDNA Libraries 2Generate High-Quality, Directional Plasmid cDNA Libraries 3Generate High-Quality, Directional Plasmid cDNA Libraries 4Generate High-Quality, Directional Plasmid cDNA Libraries 5Generate High-Quality, Directional Plasmid cDNA Libraries 6Generate High-Quality, Directional Plasmid cDNA Libraries 7The GeneZoo or the GeneJungle? 2The GeneZoo or the GeneJungle? 3The GeneZoo or the GeneJungle? 4The GeneZoo or the GeneJungle? 5The GeneZoo or the GeneJungle? 6The GeneZoo or the GeneJungle? 7The GeneZoo or the GeneJungle? 8The GeneZoo or the GeneJungle? 9The GeneZoo or the GeneJungle? 10
(Date:9/18/2014)... of the fish world, are the ideal animal in ... They,ve moved from the ocean into tens of thousands ... time changing their skeleton to adapt to the new ... of sticklebacks now have turned up one of the ... simple change in that gene,s regulation in a freshwater ...
(Date:9/17/2014)... From accessible and affordable health care to reproductive ... depend on the ability of people to identify ... openly and respectfully, and find the most defensible ... practices to support these societal conversations?, The Hastings ... of Bioethical Issues have teamed up to publish ...
(Date:9/17/2014)... started in 2000 as an EC-FP5 four-year project, delivering ... steady progress and successful participations in several EC projects, ... Observation Network project (EU BON), to increase the ... and to extend the general dissemination of the Fauna ... has applied its novel e-Publishing tools to prepare ...
Breaking Biology News(10 mins):Counting fish teeth reveals regulatory DNA changes behind rapid evolution, adaptation 2Counting fish teeth reveals regulatory DNA changes behind rapid evolution, adaptation 3Why bioethics literacy matters 2Why bioethics literacy matters 3Contributions on Fauna Europaea: Data papers as innovative model on expert involvement 2
... to find a DNA-based test to determine the sex ... sturgeon genome contains trematode genes that didn,t originally belong ... causes a sexually transmitted disease in humans. Genetics ... found the parasite and pathogen genes while analyzing DNA ...
... have developed a rapid, high-throughput screening method for prevention ... Munkongdee et al, "Rapid diagnosis of α-thalassemia by melting ... The Journal of Molecular Diagnostics . α-Thalassemia ... in the production of a component of hemoglobin. ...
... A flyover of Belize,s thick jungles has revolutionized archaeology ... by one of the most-studied ancient civilizations -- the ... NASA-funded research project in April 2009 that collected the ... days. Aboard a Cessna 337, LiDAR (Light Detection ...
Cached Biology News:Lake sturgeon have genes from parasite, signs of human STD 2Space technology revolutionizes archaeology, understanding of Maya 2Space technology revolutionizes archaeology, understanding of Maya 3
... For separation and fractionation of ... of nuclei from cytosolic proteins ... complexity, greatly facilitating study of ... nucleic acid binding proteins (e.g., ...
... PEP-126 is an 18 amino acid synthetic peptide whose sequence corresponds ... this peptide is (amino to carboxy terminus): M(1) - A - ... - A - S - P - R - D - ... This peptide may be used for neutralization and control experiments with ...
... RNA OligoMix or individual RNA sequences from high ... custom small RNAs from LC Sciences. These products ... to millions) of DESIGNED sequences delivered in a ... each containing a single verified RNA sequence. This ...
... automated bioresearch: Developed for a wide ... on decades of experience in Luminescence ... bioresearch • Holographic gratings for reduced ... ease-of-use • Pulsed Xenon lamp reduces ...
Biology Products: